Navigation Links
3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court

LONDON, February 29, 2012 /PRNewswire/ --

In the latest development in an ongoing global legal dispute, 3M Company (3M) has withdrawn a lawsuit it filed in a New York court against Harvey Boulter, the CEO of investment fund manager Porton Group.

The termination of 3M's lawsuit in New York follows a decision earlier this month by a Washington DC federal judge ruling that 3M's "blackmail" claim against the Porton Group's Washington DC attorney was invalid.

3M's withdrawal of the case in New York also comes in the wake of Porton's victory in the High Court in London last November, where 3M was held liable for damages for breach of its contractual obligations over its failure to develop a test to track MRSA in hospitals after buying the base technology from a consortium led by Porton.

Porton Group CEO, Harvey Boulter, said: "I am delighted that 3M has withdrawn its New York lawsuit. 3M made unfounded accusations in the US designed to deflect attention from the case in the UK, where 3M was held liable for breach of contract.

"3M's spurious 'blackmail' claims had absolutely no merit. I am pleased that the New York case has been closed on this sham of a dispute."

The decision coincides with the departure of Sir George Buckley as President and CEO of 3M last week (24 February). The legal wrangle was ignited publically when 3M falsely alleged that Mr Boulter had threatened, after a meeting with the then UK Defence Secretary Liam Fox, to use political contacts to have Sir George stripped of his knighthood unless 3M paid Porton $30 million to settle the contract dispute.

Notes to Editors:

For further information please contact Eben Black on +44-7968-559-198 or or Anna Brown on +44-7834-570-464 or

This release supersedes that issued on the same subject on February 23.

SOURCE Porton Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WHO Withdraws Notice of Concern for Mylans Matrix Unit
2. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
3. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
4. US Patent Office Rejects 95% of Verathon Claims in Patent Case With Aircraft Medical
5. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
6. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
7. The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management
8. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
9. Despite claims, UK did not gas Iraqis in the 1920s, new research finds
10. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
11. False Claims by Supporters Swirl Around Hayashi Bill
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
Breaking Biology Technology:
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... , Oct. 23, 2015 Research and ... the "Global Voice Recognition Biometrics Market 2015-2019" ... --> The global voice recognition biometrics ... 2014-2019. --> --> ... has been prepared based on an in-depth market analysis ...
(Date:10/22/2015)... SYNA ), a leading developer of human interface solutions, today reported ... --> --> Net revenue for ... comparable quarter last year to $470.0 million. Net income for the ... diluted share. --> --> ... 39 percent over the prior year period to $56.9 million, or ...
Breaking Biology News(10 mins):